Overview

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

Status:
RECRUITING

Trial end date:
2027-03-30

Target enrollment:

Participant gender:

Summary

This clinical study is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (otaplimastat) and thrombolytic standard of care in acute ischemic stroke patient. As a standard of care, thrombolytic therapy (for instance, recombinant tissue plasminogen activator) will be administered. When reperfusion is not achieved in spite of thrombolytic therapy, endovascular therapy can be performed.

Phase:

PHASE3

Details

Lead Sponsor:

Shin Poong Pharmaceutical Co. Ltd.

Treatments:

otaplimastat